Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | IL6 | P05231 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | GLUL | P15104 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17852532 | 1.00 | LMNA (0.65) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL11650163 | 0.84 | LMNA (0.70) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL19073469 | 0.82 | LMNA (0.67) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL13259847 | 0.82 | LMNA (0.67) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL14962034 | 0.82 | LMNA (0.67) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL17775770 | 0.81 | LMNA (0.77) | LMNAMAPTCYP19A1CYP3A4 | |
| SCHEMBL12857031 | 0.81 | LMNA (0.69) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL1144570 | 0.81 | LMNA (0.69) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL27046922 | 0.80 | LMNA (0.75) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL27046895 | 0.79 | LMNA (0.70) | LMNAMAPTCYP19A1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102423-A1 | Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| US-20040102423-A1 | Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | disclosed |
| US-20040097476-A1 | Use of low dose amount of aldosterone antagonist for treatment of cardiovascular disease | G.D. SEARLE & CO. | 2004-05-20 | — | — | US | disclosed |
| US-20040067915-A1 | Method to treat cardiofibrosis with a combination of an angiotensin II antagonist and spironolactone | G.D. SEARLE & CO. (US) | 2004-04-08 | — | — | US | disclosed |
| US-20030144213-A1 | Combination therapy of angiotensin converting enzyme inhibitor, side-effect reduced amount of aldosterone antagonist and diuretic for treatment of cardiovascular disease | G.D. SEARLE & CO. | 2003-07-31 | — | — | US | disclosed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040256-A1 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION OF AN ANGIOTENSIN II ANTAGONIST AND SPIRONOLACTONE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067915-A1 | Method to treat cardiofibrosis with a combination of an angiotensin II antagonist and spironolactone | AGTR2, AGTR1, NR3C2 | LMNA 344/4885MAPT 4652/4885CYP19A1 638/4885 |
| US-20040102423-A1 | Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure | AGTR2, AGTR1, NR3C2 | LMNA 2097/4885MAPT 4138/4885CYP19A1 1754/4885 |
| US-20030144213-A1 | Combination therapy of angiotensin converting enzyme inhibitor, side-effect reduced amount of aldosterone antagonist and diuretic for treatment of cardiovascular disease | ACE, REN, AGTR1 | LMNA 1924/4885MAPT 3517/4885CYP19A1 1979/4885 |
| US-20040097476-A1 | Use of low dose amount of aldosterone antagonist for treatment of cardiovascular disease | NR3C2, REN, AGTR1 | LMNA 1491/4885MAPT 4274/4885CYP19A1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.